PL1771208T3 - Zastosowanie radioznakowanych pochodnych tioflawiny w obrazowaniu amyloidu dla oceny terapii antyamyloidowej - Google Patents

Zastosowanie radioznakowanych pochodnych tioflawiny w obrazowaniu amyloidu dla oceny terapii antyamyloidowej

Info

Publication number
PL1771208T3
PL1771208T3 PL05787557T PL05787557T PL1771208T3 PL 1771208 T3 PL1771208 T3 PL 1771208T3 PL 05787557 T PL05787557 T PL 05787557T PL 05787557 T PL05787557 T PL 05787557T PL 1771208 T3 PL1771208 T3 PL 1771208T3
Authority
PL
Poland
Prior art keywords
amyloid
thioflavin
therapies
imaging
radiolabeled derivatives
Prior art date
Application number
PL05787557T
Other languages
English (en)
Inventor
William E Klunk
Chester A Mathis Jr
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of PL1771208T3 publication Critical patent/PL1771208T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL05787557T 2004-07-02 2005-07-01 Zastosowanie radioznakowanych pochodnych tioflawiny w obrazowaniu amyloidu dla oceny terapii antyamyloidowej PL1771208T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58448704P 2004-07-02 2004-07-02
PCT/US2005/023617 WO2006014381A2 (en) 2004-07-02 2005-07-01 Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies
EP05787557.7A EP1771208B1 (en) 2004-07-02 2005-07-01 Use of thioflavin radiolabeled derivatives in amyloid imaging for assessing anti-amyloid therapies

Publications (1)

Publication Number Publication Date
PL1771208T3 true PL1771208T3 (pl) 2013-11-29

Family

ID=35504952

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05787557T PL1771208T3 (pl) 2004-07-02 2005-07-01 Zastosowanie radioznakowanych pochodnych tioflawiny w obrazowaniu amyloidu dla oceny terapii antyamyloidowej

Country Status (16)

Country Link
US (4) US8147798B2 (pl)
EP (1) EP1771208B1 (pl)
JP (1) JP2008505115A (pl)
CN (2) CN101137397A (pl)
AU (1) AU2005270026A1 (pl)
BR (1) BRPI0512893B8 (pl)
CA (2) CA2587248C (pl)
CY (1) CY1114644T1 (pl)
DK (1) DK1771208T3 (pl)
ES (1) ES2427963T3 (pl)
NO (1) NO339187B1 (pl)
PL (1) PL1771208T3 (pl)
PT (1) PT1771208E (pl)
RU (1) RU2007104107A (pl)
SI (1) SI1771208T1 (pl)
WO (1) WO2006014381A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
CN101355940B (zh) * 2005-09-16 2013-03-27 匹兹堡大学高等教育联邦体系 用于检测具有至少一种促淀粉样变蛋白的淀粉样沉积物的体内或体外方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008118122A2 (en) 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
DK2182983T3 (da) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
RU2475267C2 (ru) * 2007-08-30 2013-02-20 Джи-И Хелткер Лимитед Радиофармацевтическая композиция
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5603855B2 (ja) 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
CA2737028C (en) * 2008-09-23 2017-06-27 Wista Laboratories Ltd. Ligands for aggregated tau molecules
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2365974B1 (en) * 2008-11-06 2013-12-25 SNU R&DB Foundation Fluorinated benzothiazole derivatives, preparation method thereof and imaging agent for diagnosing altzheimer's disease using the same
US20130084245A1 (en) * 2010-02-25 2013-04-04 Wyeth Llc Pet monitoring of a-beta-directed immunotherapy
WO2014004664A2 (en) * 2012-06-27 2014-01-03 Mayo Foundation For Medical Education And Research Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
US9422286B2 (en) 2014-01-27 2016-08-23 Washington University Metal-binding bifunctional compounds as diagnostic agents for Alzheimer's disease
CA2994178C (en) 2015-08-18 2024-03-19 The Regents Of The University Of California Nitroxide containing amyloid binding agents for imaging and therapeutic uses
BR112018068066B1 (pt) * 2016-03-11 2023-11-28 Ac Immune Sa Compostos bicíclicos e seu uso, composição diagnóstica e farmacêutica, misturas, métodos de coleção de dados para diagnóstico, para determinar uma predisposição a, para monitorar transtorno residual e para prever a capacidade de resposta de um paciente sofrendo de transtorno ou anormalidade associado com agregados de alfa-sinucleína, métodos para determinar a quantidade de agregados de alfa-sinucleína e para preparar um composto, kit teste e kit para preparar uma preparação radio farmacêutica
US20230158178A1 (en) * 2020-03-16 2023-05-25 Emory University Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof
CN116953008B (zh) * 2023-06-14 2024-10-22 汕头大学医学院第二附属医院 基于磁共振成像的β淀粉样蛋白浓度检测方法及系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092003A1 (en) * 1999-12-29 2003-05-15 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of Alzheimer's disease
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2444214A1 (en) * 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
AU2003212490A1 (en) 2002-02-13 2003-09-04 Amersham Plc Benzothiazole derivatives for in vivo imaging of amyloid plaques
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
GB0307855D0 (en) 2003-04-04 2003-05-14 Novartis Ag Organic compounds
JP2008505116A (ja) * 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ アミロイド沈着を伴う疾患の前駆形態の診断方法

Also Published As

Publication number Publication date
ES2427963T3 (es) 2013-11-05
BRPI0512893B1 (pt) 2019-12-24
AU2005270026A1 (en) 2006-02-09
US20080219931A1 (en) 2008-09-11
SI1771208T1 (sl) 2013-10-30
NO20070593L (no) 2007-03-27
CN101137397A (zh) 2008-03-05
US8343457B2 (en) 2013-01-01
US20120177572A1 (en) 2012-07-12
US8147798B2 (en) 2012-04-03
WO2006014381A3 (en) 2007-01-18
WO2006014381A2 (en) 2006-02-09
CA2830939A1 (en) 2006-02-09
CA2587248A1 (en) 2006-02-09
US8580229B2 (en) 2013-11-12
NO339187B1 (no) 2016-11-14
WO2006014381A9 (en) 2006-04-13
EP1771208B1 (en) 2013-06-19
BRPI0512893A (pt) 2008-04-15
CA2830939C (en) 2017-02-28
DK1771208T3 (da) 2013-09-02
EP1771208A2 (en) 2007-04-11
JP2008505115A (ja) 2008-02-21
PT1771208E (pt) 2013-09-24
US20130045164A1 (en) 2013-02-21
CY1114644T1 (el) 2016-10-05
CN102973954A (zh) 2013-03-20
CA2587248C (en) 2014-01-07
BRPI0512893B8 (pt) 2021-07-27
US20140105820A1 (en) 2014-04-17
RU2007104107A (ru) 2008-08-10

Similar Documents

Publication Publication Date Title
SI1771208T1 (sl) Uporaba tioflavinskih radioaktivnih derivatov v amiloidnih posnetkih za ocenjevanje proti amiloidnih terapij
IL183946A0 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
IL195044A0 (en) Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
CY2013024I2 (el) Παραγωγα στυρυλοπυριδινης και η χρηση τους για συνδεση κι απεικονιση πλακων αμυλοειδους
EP1718194A4 (en) MRI PROBE FOR THE PICTORIAL PROSTATE PRESENTATION
DK1886112T3 (da) Fremgangsmåde til Måling af metabolismen af neuralt afledte biomolekyler in vivo
GB2464902B (en) Methods for evaluating candidate therapeutic agents
ZA201002926B (en) Use of anti-amyloid beta antibody in ocular disease
IL195271A0 (en) Composition for diagnosing amyloid-related disease
GB2463825B (en) Compensated caliper using combined acoustic and density measurements
EP2223121A4 (en) METHOD AND KIT FOR USE IN THE DIFFERENTIATION OF IBD AND IBS AND IN COMPLEMENTARY DISTINCTION BETWEEN DIFFERENT TYPES OF IBD DISEASES
IL199201A (en) Acetylene history and their use for linking and imaging of amyloid layers
PL1824523T3 (pl) Sposób obrazowania serca przy zastosowaniu hiperspolaryzowanego 13C-pirogronianu
IL182404A0 (en) Mutated amyloid protein
PL2194993T3 (pl) Metody badania przesiewowego leków z użyciem nieinwazyjnego obrazowania in vivo
GB0523506D0 (en) Novel in vivo imaging compounds
ZA201102689B (en) Piperazine derivatives for binding and imaging amyloid plaques and their use
GB0513812D0 (en) Compounds for imaging and therapy
GB0522899D0 (en) Verification of continuity
EP1870710A4 (en) BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
ZA200705104B (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
ZA200809833B (en) Composition for diagnosing amyloid-related disease
GB0515974D0 (en) Compounds and imaging methods
GB0508943D0 (en) MRI imaging
TWI349773B (en) Method of x-ray reflectance measurement